http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-072471-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2aafc2f3c2921b1f2d3009ebecfba297 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| filingDate | 2009-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-072471-A1 |
| titleOfInvention | BENZOXACINES AND BENZOTIACINES WITH US INHIBITING ACTIVITY, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES IN PAIN TREATMENT. |
| abstract | Benzoxacins, benzothiazines and related compounds that inhibit nitric oxide synthetase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthetase (nNOS) preferably to other NOS isoforms. These NOS inhibitors alone or in combination with other pharmaceutically active agents, can be used for the treatment or prevention of various medical conditions related to pain. Claim 1: A compound having the formula (1) wherein: Q is O- (CHR6) 1-3 or S- (CHR6) 1-3; R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkylaryl, optionally substituted C1-4 alkylheterocyclyl, or optionally substituted C2-9 heterocyclyl, optionally substituted C3-8 cycloalkyl, C1 alkylcycloalkyl -4 optionally substituted, or - (CR1AR1B) nNR1CR1D; R1A and R1B are, independently, H, hydroxy, halo, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-4 alkylcycloalkyl, optionally substituted C1-4 alkylaryl, optionally substituted C1-4 alkyl heterocyclyl, optionally substituted C1-4 alkylheteroaryl, optionally substituted C3-8 cycloalkyl, optionally substituted C2-9 heterocyclyl or R1A and R1B combine to form = O; R1C and R1D are, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-4 alkylcycloalkyl, optionally substituted C1-4 alkylaryl, optionally substituted C1-4 alkylheterocyclyl, C1-4 alkyl heteroaryl optionally substituted, optionally substituted C3-8 cycloalkyl, optionally substituted C2-9 heterocyclyl or an N-protecting group, or R1C and R1D combine to form an optionally substituted C2-9 heterocyclyl or an N-protecting group; n is an integer between 1-6; each of R2 and R3 is independently H, hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkylaryl, optionally substituted C2-9 heterocyclyl, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, (CH2) r2NHC (NH) R2A, or (CH2) r2NHC (S) NHR2A, or optionally substituted C1-4 alkylheterocyclyl, wherein r2 is an integer from 0 to 2, R2A is C1 alkyl -6 optionally substituted, optionally substituted C6-10 aryl, optionally substituted C1-4 alkylaryl, optionally substituted C2-9 heterocyclyl, optionally substituted C1-4 alkylheterocyclyl, optionally substituted C1-6 thioalkoxy, optionally substituted thioalkylaryl, optionally aryloyl substituted, optionally substituted thioalkylheterocyclyl, or optionally substituted amino; each of R4 and R5 is independently H, hal, (CH2) r2NHC (NH) R2A, or (CH2) r2NHC (S) NHR2A; wherein Y1 and Y2 are each H, or Y1 and Y2 together are = O, or Y1 and Y2 are independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkylaryl, heterocyclyl Optionally substituted C2-9, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, or optionally substituted C1-4 alkylheterocyclyl; wherein only one of R2, R3, R4, and R5 is (CH2) r2NHC (NH) R2A or (CH2) r2NHC (S) NHR2A; or a pharmaceutically acceptable salt or a prodrug thereof. |
| priorityDate | 2008-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.